08006785869
info@breastcancerresearchaid.org.uk

Beneficiaries

To help save lives through the ongoing research of breast cancer

The Royal Marsden Hospital

We are very grateful to Breast Cancer Research Aid for your support of The Royal Marsden’s C-TRAK trial, an innovative research project that has the potential to change the lives of women diagnosed with triple negative breast cancer in the UK and world-wide.

The Royal Marsden was founded thanks to contemporary philanthropists and your generosity is continuing this important tradition. Thank you for helping us to drive forward advances in breast cancer research and provide patients with the best quality of life.

C-TRAK: Developing a novel way to detect and treat breast cancer
Breast cancer is the most common cancer in the UK, with around 55,000 women diagnosed every year. Of those women, 15 per cent will be diagnosed with triple negative breast cancer (TNBC).

Standard treatment for this type of cancer includes surgery and chemotherapy. However, TNBC is difficult to treat because it does not respond to common therapies, such as tamoxifen or Herceptin.

Furthermore, TNBC is more likely to recur than other breast cancers. Sadly, by the time TNBC returns and has grown large enough to be seen on a CT or MRI scan, the disease is often untreatable.

To meet this challenge, The Royal Marsden is leading C-TRAK: a two-part clinical trial that will assess if a blood test can detect TNBC as soon as it recurs and investigate a new therapy option to successfully treat the disease before it becomes life-threatening.

Read More…

Post a comment